MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-02-2026
Twist Bioscience Corporation Cost of Revenue 2011-2026 | TWST
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Twist Bioscience Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 186 M | 180 M | 155 M | 119 M | 80.6 M | 61.4 M | 47.4 M | 32.2 M | 24 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 186 M | 24 M | 98.4 M |
Quarterly Cost of Revenue Twist Bioscience Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 49.7 M | - | 44.8 M | 46.8 M | 45.9 M | - | 46.2 M | 44.4 M | 42.5 M | - | 41.8 M | 41.7 M | 29.4 M | 87.7 M | 31 M | 29.7 M | 27.1 M | 58.1 M | 20.9 M | 19 M | 18.2 M | 43.8 M | 16.5 M | 18.2 M | 13.8 M | 35 M | 11.4 M | 13.8 M | 11.9 M | 23.1 M | 7.5 M | 11.9 M | 7.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 87.7 M | 7.5 M | 31.3 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 18.56 | 10.74 % | $ 196 M |  China |
 |
Agilent Technologies
A
|
2.91 B | - | - | $ 34.4 B |  USA |
 |
Castle Biosciences
CSTL
|
71 M | $ 18.88 | 4.02 % | $ 547 M | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 16.19 | 1.44 % | $ 490 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 20.49 | -0.58 % | $ 1.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Lantheus Holdings
LNTH
|
600 M | - | - | $ 6.5 B | USA |
 |
Myriad Genetics
MYGN
|
248 M | $ 3.62 | -2.95 % | $ 335 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 1.63 | 1.87 % | $ 2.17 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 8.36 | 1.21 % | $ 1.07 B | USA |
 |
Natera
NTRA
|
158 M | $ 196.91 | 0.81 % | $ 19.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.78 B | $ 25.5 | -0.51 % | $ 24.2 B |  Niderland |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Personalis
PSNL
|
53.9 M | $ 6.71 | 5.01 % | $ 599 M | USA |
 |
Guardant Health
GH
|
349 M | $ 98.66 | 0.19 % | $ 12.4 B | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 5.82 | 5.82 % | $ 243 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 117.09 | -0.25 % | $ 9.66 B |  Irlanda |
 |
Illumina
ILMN
|
1.51 B | $ 143.24 | -1.21 % | $ 22.8 B | USA |
 |
Soleno Therapeutics
SLNO
|
2.7 M | $ 52.99 | 0.08 % | $ 2.69 B | USA |
 |
Trinity Biotech plc
TRIB
|
40.1 M | $ 0.58 | -1.08 % | $ 208 M | Irlanda |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
4.81 M | $ 2.41 | 7.11 % | $ 5.54 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 254.02 | -0.16 % | $ 21.1 B | USA |
 |
Waters Corporation
WAT
|
363 M | $ 333.21 | -0.51 % | $ 19.8 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Neogen Corporation
NEOG
|
473 M | $ 8.43 | -2.99 % | $ 1.83 B | USA |